Last update 01 Nov 2024
Bonentai (Shandong) Biomedical Technology Group Co., Ltd.

Bonentai (Shandong) Biomedical Technology Group Co., Ltd.

Private Company|
2003|
Shandong Sheng, China
|
www.bangentai.com

Overview

Tags

Neoplasms
Hemic and Lymphatic Diseases
Immune System Diseases
Cell therapy
CAR-T
Nanobody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms27
Immune System Diseases10
Hemic and Lymphatic Diseases10
Endocrinology and Metabolic Disease9
Nervous System Diseases8
Infectious Diseases2
Top 5 Drug TypeCount
Cell therapy11
CAR-T10
Nanobody7
Small molecule drug4
Induced pluripotent stem cells (iPSC)4
Top 5 TargetCount
CLDN18.2(Claudin 18.2)1
GPC3(Glypican-3)1
CD30(Tumor necrosis factor receptor superfamily member 8)1
CEACAM7(CEA cell adhesion molecule 7)1
MUC16(Mucin-16)1

Related

38
Drugs associated with Bonentai (Shandong) Biomedical Technology Group Co., Ltd.
TH-012
Target-
Mechanism-
Active Org.
Jinan Taihe Pharmaceutical Technology Co., Ltd.Jinan Taihe Pharmaceutical Technology Co., Ltd.
Originator Org.
Jinan Taihe Pharmaceutical Technology Co., Ltd.Jinan Taihe Pharmaceutical Technology Co., Ltd.
Active Indication
Pancreatic Cancer [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
TH-008
Target-
Mechanism
Gene transference [+1]
Active Org.
Jinan Taihe Pharmaceutical Technology Co., Ltd.Jinan Taihe Pharmaceutical Technology Co., Ltd.
Originator Org.
Jinan Taihe Pharmaceutical Technology Co., Ltd.Jinan Taihe Pharmaceutical Technology Co., Ltd.
Active Indication
Non-Hodgkin Lymphoma
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
TH-007
Target-
Mechanism
Gene transference [+1]
Active Org.
Jinan Taihe Pharmaceutical Technology Co., Ltd.Jinan Taihe Pharmaceutical Technology Co., Ltd.
Originator Org.
Jinan Taihe Pharmaceutical Technology Co., Ltd.Jinan Taihe Pharmaceutical Technology Co., Ltd.
Active Indication
Burkitt Lymphoma
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Bonentai (Shandong) Biomedical Technology Group Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Bonentai (Shandong) Biomedical Technology Group Co., Ltd.
Login to view more data
100 Deals associated with Bonentai (Shandong) Biomedical Technology Group Co., Ltd.
Login to view more data
100 Translational Medicine associated with Bonentai (Shandong) Biomedical Technology Group Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
34
3
Phase 1 Clinical
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
TH-008
Non-Hodgkin Lymphoma
More
Phase 1
TH-007
Burkitt Lymphoma
More
Phase 1
TH-012
Pancreatic Cancer
More
Phase 1
BET066-01
Solid tumor
More
Preclinical
TH007-01
 ( CD30 )		Hodgkin's Lymphoma
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free